Retroviral Integrase Inhibitor Pharmacokinetics
From Proteopedia
(Difference between revisions)
(New page: {| class="wikitable" border="1" width="55%" style="text-align:center" |- ! colspan="4" align="center"| Retroviral Integrase Inhibitor Pharmacokinetics |- ! Parameter ! Raltegravir...) |
|||
| Line 1: | Line 1: | ||
| - | {| class="wikitable" border="1" width=" | + | {| class="wikitable" border="1" width="100%" style="text-align:center" |
|- | |- | ||
! colspan="4" align="center"| Retroviral Integrase Inhibitor [[Pharmacokinetics]] | ! colspan="4" align="center"| Retroviral Integrase Inhibitor [[Pharmacokinetics]] | ||
Revision as of 09:21, 10 December 2010
| Retroviral Integrase Inhibitor Pharmacokinetics | |||
|---|---|---|---|
| Parameter | Raltegravir | Elvitegravir | MK-2048 |
| Tmax (hr) | 1.8 | 2-4 | N/A |
| Cmax (ng/ml) | 4253 | 2070 | N/A |
| Bioavailability (%) | 32 | ~30 | N/A |
| Protein Binding (%) | 83 | N/A | N/A |
| T1/2 (hr) | 10.8 | 7.6 | N/A |
| AUC (ng/ml/hr) | 10168 | 21200 | N/A |
| Dosage (mg) | 400 | 150 | N/A |
| Metabolism | Hepatic - (UGT1A1) | Hepatic - (CYP3A4) | N/A |
For Pharmacokinetic Data References, See: References
